You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 21-27 of 27 results found

Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs)

Inventors at the National Cancer Institute (NCI) have developed chimeric antigen receptors (CARs) that target two B cell surface antigens, CD19 and CD22, improving treatment of B-cell malignancies, such as acute lymphoblastic leukemia (ALL). NCI is actively seeking parties interested in licensing this invention to commercialize the bicistronic CAR construct targeting CD19 and CD22 for immunotherapy.
  • Therapeutics

Therapeutics for Neurodegenerative Disorders and Cancer Using Lenalidomide Analogs

Novel thalidomide analogs and their use as immunomodulatory agents are disclosed in this invention by scientists at the National Institute on Aging (NIA). These therapeutic compounds could reduce chronic systemic and central nervous system inflammation. The NIA seeks licensing or co-development partners to commercialize this technology.
  • Therapeutics

SLCO1B3 Genotyping to Predict a Survival Prognosis of Prostate Cancer

This invention identifies two polymorphic genetic markers in the SLCO1B3 (formerly SLC21A8) gene, called 334T>G and 699G>A, that can be measured in genomic DNA obtained from a blood sample to predict survival from diagnosis of prostate cancer in that individual patient.
  • Diagnostics

Polarimetric Accessory for Colposcope

The National Institute of Child Health and Human Development (NICHD) seeks licensing and/or co-development of a colposcope attachment that resolves tissue borne specular flare.
  • Devices

T-Cell Therapy Against Patient-Specific Cancer Mutations

Scientists at the National Cancer Institute developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. NCI seeks parties interested in collaborative research to co-develop or license T-cell therapy against cancer mutations
  • Therapeutics

Pages